Department of Cardiothoracic Surgery, St George Hospital, Gray Street Kogarah, Sydney, Australia.
Department of Cardiothoracic Surgery, John Hunter Hospital, Lookout Road, Newcastle, Australia.
J Cardiothorac Surg. 2022 Aug 13;17(1):181. doi: 10.1186/s13019-022-01930-7.
Atrial fibrillation (AF) is the most common arrhythmia. Hybrid convergent ablation (HCA) is an emerging procedure for treating longstanding AF with promising results. HCA consists of a subxiphoid, surgical ablation followed by completion endocardial ablation. This meta-analysis of randomized control trials (RCT's) and propensity score-matched studies aims to examine the efficacy and safety of HCA compared to endocardial catheter ablation (ECA) alone on patients with AF.
This review was written in accordance with preferred reporting items for systematic reviews and meta-analyses recommendations and guidance. The primary outcome for the analysis was freedom from AF (FFAF) at final follow up. Secondary outcomes were mortality and significant complications such as tamponade, sternotomy, esophageal injury, atrio-esophageal fistulae post procedurally.
Four studies where included, with a total of 233 patients undergoing HCA and 189 patients undergoing ECA only. Pooled analysis demonstrated that HCA cohorts had significantly higher rates of FFAF than ECA cohorts, with an OR of 2.78 (95% CI 1.82-4.24, P < 0.01, I = 0). Major post-operative complications were observed in significantly more patients in the HCA group, with an OR of 5.14 (95% CI 1.70-15.54, P < 0.01). There was only one death reported in the HCA cohorts, with no deaths in the ECA cohort.
HCA is associated with a significantly higher FFAF than ECA, however, it is associated with increased post-procedural complications. There was only one death in the HCA cohort. Large RCT's comparing the HCA and ECA techniques may further validate these results.
心房颤动(AF)是最常见的心律失常。杂交汇聚消融(HCA)是一种治疗慢性心房颤动的新兴方法,具有良好的效果。HCA 由剑突下、外科消融和随后的完成心内膜消融组成。本荟萃分析旨在研究 HCA 与单独的心内膜导管消融(ECA)相比,在治疗 AF 患者时的疗效和安全性。
本综述的撰写符合系统评价和荟萃分析建议和指南的首选报告项目。分析的主要结局是最终随访时的 AF 无复发(FFAF)。次要结局是死亡率和重大并发症,如术后填塞、开胸术、食管损伤、房室瘘。
纳入了四项研究,共 233 例患者接受 HCA 治疗,189 例患者仅接受 ECA 治疗。荟萃分析显示,HCA 组的 FFAF 率明显高于 ECA 组,OR 为 2.78(95% CI 1.82-4.24,P<0.01,I=0)。HCA 组术后主要并发症发生率明显较高,OR 为 5.14(95% CI 1.70-15.54,P<0.01)。HCA 组仅报告一例死亡,ECA 组无死亡。
HCA 与 ECA 相比,AF 无复发率明显更高,但术后并发症发生率增加。HCA 组只有一例死亡。比较 HCA 和 ECA 技术的大型 RCT 可能会进一步验证这些结果。